Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition

Prostate

Volumn 75, Issue 13, 2015, Pages 1341-1353

  Liu, Chengfei ^a   Lou, Wei ^a   Armstrong, Cameron ^a   Zhu, Yezi ^a,b   Evans, Christopher P ^a,c   Gao, Allen C ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

enzalutamide; interleukin 6; niclosamide; prostate cancer; Stat3

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR VARIANT 7; ENZALUTAMIDE; INTERLEUKIN 6; MYC PROTEIN; NICLOSAMIDE; PROSTATE SPECIFIC ANTIGEN; STAT3 PROTEIN; SURVIVIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN;

ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL GROWTH ASSAY; CELL INVASION; CELL INVASION ASSAY; CHROMATIN IMMUNOPRECIPITATION; CLONOGENIC ASSAY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METABOLIC INHIBITION; MIGRATION INHIBITION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WOUND HEALING; ANALOGS AND DERIVATIVES; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; PROSTATE TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG INTERACTIONS; HUMANS; MALE; NICLOSAMIDE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STAT3 TRANSCRIPTION FACTOR;

EID: 84939271612     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.23015     Document Type: Article

References (36)

1. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS,. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197.
2. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B,. Enzalutamide in metastatic prostate cancer before chemotherapy. New Engl J Med 2014; 371: 424-433.
3. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C2, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM,. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 2014; 510: 278-282.
4. Lin TH, Lee SO, Niu Y, Xu D, Liang L, Li L, Yeh SD, Fujimoto N, Yeh S, Chang C,. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis. J Biol Chem 2013; 288: 19359-19369.
5. Lin TH, Izumi K, Lee SO, Lin WJ, Yeh S, Chang C,. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis 2013; 4: e764.
6. Liu C, Zhu Y, Lou W, Cui Y, Evans CP, Gao AC,. Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate 2014; 74: 201-209.
7. Bromberg J, Wang TC,. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009; 15: 79-80.
8. Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, Gao AC,. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res 2014; 20: 3198-3210.
9. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC,. Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate 2000; 42: 239-242.
10. DeMiguel F, Lee SO, Lou W, Xiao X, Pflug BR, Nelson JB, Gao AC,. Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice. Prostate 2002; 52: 123-129.
11. Liu C, Nadiminty N, Tummala R, Chun JY, Lou W, Zhu Y, Sun M, Evans CP, Zhou Q, Gao AC,. Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes Cancer 2011; 2: 151-159.
12. Liu C, Zhu Y, Lou W, Nadiminty N, Chen X, Zhou Q, Shi XB, deVere White RW, Gao AC,. Functional p53 determines docetaxel sensitivity in prostate cancer cells. Prostate 2013; 73: 418-427.
13. Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, Evans CP, Gao AC,. Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer. Cancer Res 2015; Feb 3. pii: canres.3080.
14. Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans CP, Gao AC,. Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther 2013; 12: 1829-1836.
15. Cui Y, Nadiminty N, Liu C, Lou W, Schwartz CT, Gao AC,. Upregulation of glucose metabolism by NF-kappaB2/p52 mediates enzalutamide resistance in castration-resistant prostate cancer cells. Endocr-Relat Cancer 2014; 21: 435-442.
16. Li R, Hu Z, Sun SY, Chen ZG, Owonikoko TK, Sica GL, Ramalingam SS, Curran WJ, Khuri FR, Deng X,. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Mol Cancer Ther 2013; 12: 2200-2212.
17. Safdari Y, Khalili M, Farajnia S, Asgharzadeh M, Yazdani Y, Sadeghi M,. Recent advances in head and neck squamous cell carcinoma-a review. Clin Biochem 2014; 47: 1195-1202.
18. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC,. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003; 9: 370-376.
19. Hedvat M, Huszar D, Herrmann A, Gozgit JM, Schroeder A, Sheehy A, Buettner R, Proia D, Kowolik CM, Xin H, Armstrong B, Bebernitz G, Weng S, Wang L, Ye M, McEachern K, Chen H, Morosini D, Bell K, Alimzhanov M, Ioannidis S, McCoon P, Cao ZA, Yu H, Jove R, Zinda M,. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009; 16: 487-497.
20. Yu H, Kortylewski M, Pardoll D,. Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007; 7: 41-51.
21. Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Nevalainen MT,. Stat3 promotes metastatic progression of prostate cancer. Am J Pathol 2008; 172: 1717-1728.
22. Sun M, Liu C, Nadiminty N, Lou W, Zhu Y, Yang J, Evans CP, Zhou Q, Gao AC,. Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion. Prostate 72: 82-89.
23. Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT,. Skeletal related events, bone metastasis and survival of prostate cancer: A population based cohort study in Denmark (1999 to 2007). J Urol 2010; 184: 162-167.
24. Holzapfel BM, Wagner F, Loessner D, Holzapfel NP, Thibaudeau L, Crawford R, Ling MT, Clements JA, Russell PJ, Hutmacher DW,. Species-specific homing mechanisms of human prostate cancer metastasis in tissue engineered bone. Biomaterials 2014; 35: 4108-4115.
25. Roodman GD,. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-1664.
26. Chun JY, Nadiminty N, Dutt S, Lou W, Yang JC, Kung HJ, Evans CP, Gao AC,. Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res 2009; 15: 4815-4822.
27. Zhu Y, Liu C, Cui Y, Nadiminty N, Lou W, Gao AC,. Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST). Prostate 2014; 74: 1086-1094.
28. Dang CV,. MYC on the path to cancer. Cell 2012; 149: 22-35.
29. Chu XY, Chen LB, Wang JH, Su QS, Yang JR, Lin Y, Xue LJ,. Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol 2012; 105: 520-528.
30. Tai CJ, Chin-Sheng H, Kuo LJ, Wei PL, Lu HH, Chen HA, Liu TZ, Liu JJ, Liu DZ, Ho YS, Wu CH, Chang YJ,. Survivin-mediated cancer cell migration through GRP78 and epithelial-mesenchymal transition (EMT) marker expression in Mahlavu cells. Ann Surg Oncol 2012; 19: 336-343.
31. Knight BB, Oprea-Ilies GM, Nagalingam A, Yang L, Cohen C, Saxena NK, Sharma D,. Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells. Endocr-Relat Cancer 2011; 18: 413-428.
32. Hodge DR, Hurt EM, Farrar WL,. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005; 41: 2502-2512.
33. Grivennikov S, Karin M,. Autocrine IL-6 signaling: A key event in tumorigenesis?. Cancer Cell 2008; 13: 7-9.
34. Chen M, Wang J, Lu J, Bond MC, Ren XR, Lyerly HK, Barak LS, Chen W,. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochem 2009; 48: 10267-10274.
35. An J, Wang C, Deng Y, Yu L, Huang H,. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep 2014; 6: 657-669.
36. Ueda T, Bruchovsky N, Sadar MD,. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002; 277: 7076-7085.